|
|
Article: Management of patients with primary central nervous system lymphoma treated with high-dose methotrexate.(Report)
- Article from:
- Clinical Journal of Oncology Nursing
- Article date:
- April 1, 2009
- Author:
CopyrightCOPYRIGHT 2009 Oncology Nursing Society. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Primary central nervous system lymphoma (PCNSL) is a rare, extranodal form of non-Hodgkin lymphoma that affects immunocompetent as well as immunocompromised patients. PCNSL tumors usually are fast growing, and symptoms develop within a few weeks (Raval, Yahalom, & DeAngelis, 2004). The tumors were treated with steroids and whole brain radiation in the past, but survival was poor. Current treatments include high-dose methotrexate (MTX), which has increased survival time and sometimes even cured PCNSL. As a result, this article will focus on immunocompetent patients who are receiving high-dose MTX as well as nursing implications for treatment.
In immunocompetent ...